Dr. Mariam Alexander
MUSC Health Hematology Oncology
86 Jonathan Lucas Street
2nd Floor, 3rd Floor
Charleston, SC 29425
(843) 792-9300
Doctor Overview
Dr. Mariam Alexander is a board-certified hematologist and medical oncologist in Charleston, South Carolina. She practices at the MUSC Health Hollings Cancer Center, where she treats patients who have complex solid tumors. Her expertise includes diseases like lung cancer and pleural mesothelioma.
Dr. Alexander earned her medical degree in 2014, followed by her PhD in molecular biology and genetics. Her hematology and oncology training took place at Montefiore Medical Center in New York. Her residency in internal medicine was performed at SUNY Upstate Medical University. She now teaches as an assistant professor of medicine and oncology at the Medical University of South Carolina.
Dr. Alexander’s clinical focus includes targeted therapies and precision cancer care. She has worked on emerging treatments and clinical trials for her center’s solid tumor program. Dr. Alexander has also published research related to lung cancer treatment and biomarkers. She focuses on personalizing care for patients with challenging tumors.
Doctor Fast Facts
Main Specialty: Medical Oncology/Hematology
Other Interests & Specialties: Chest wall tumors, clinical trials, immunotherapy, lung cancer, mesothelioma, thymic carcinoma, thymoma, thymus cancers and tracheal tumors.
Certifications, Awards & Accolades: American Board of Internal Medicine Certified in Hematology, Internal Medicine and Medical Oncology
Education & Experience:
- Medical Degree from Saba University School of Medicine
- Residency in Internal Medicine at SUNY Upstate Medical University
- Fellowship in Hematology and Oncology at Montefiore Medical Center/Albert Einstein College of Medicine
Publications
Second-line treatment strategies and clinical outcomes after progression on chemoimmunotherapy in extensive-stage small-cell lung cancer. Lung Cancer. 2025 Nov;209:108786.
Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated non-small cell lung cancer: Patient satisfaction and resource utilization results from the PALOMA-3 study. Eur J Cancer. 2025 Sept 9;227:115624.
